Full Year 2023 Investor Presentation
128
Investor presentation Full year 2023
Rest of World at a glance
Rest of World
300
Million
Diabetes trend in population
21%
DKK
billion
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Full year 2023
MS
Sales
(mDKK)
Growth²
Injectable GLP-13
8,658
45%
250
18%
60
80
100%
RybelsusⓇ
3,026
131%
Total GLP-1
11,684
61%
200
60
GLP-1 80%
Total insulin4
60
35.4%1
10,095
4%
Other Diabetes care5
434
-9%
2.4%¹
Insulin
150
60%
286
Diabetes care
22,213
27%
40
227
100
Obesity care
2,476
20%
40%
187
5.5%1
Diabetes & Obesity
20
24,689
27%
50
OAD
20%
care
Rare disease7
3,389
-31%
0
2021
0
0%
Nov
2030
2045
2018
Nov
2023
Total
28,078
15%
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Nov 2023: Novo Nordisk 59%,
Others 41%; Competitor GLP-1 value market shares, as of Nov 2023: Novo Nordisk
84%, Others 16%. OAD: Oral anti-diabetic; MS: Market Share; Note: Market values
are based on list prices; Source: IQVIA MAT, Nov 2023 value figures
2 At constant exchange rates; ³ Comprises VictozaⓇ, Ozempic®;
4 Comprises TresibaⓇ, XultophyⓇ, Levemir®, NovoMix®, Ryzodeg®, NovoRapid®
and FiaspⓇ5 Comprises Novo NormⓇ and needles; 6 Comprises SaxendaⓇ;
Comprises primarily Esperoct®, Refixia®, NovoSeven®, Novo Eight® and
NorditropinⓇView entire presentation